CEO of Retro Biosciences, Joe @BettsLaCroix, urges anti-aging startups to be ready to “go off script”. There’s need to worry about “seeming weird”. But respect moral principles must be paramount. And prioritise precision as well as speed in the work done #LongevitySummitDublin
Showing a list of recent headlines about treatments that can reverse ageing, Matt warns: ‘If you underpromise and overdeliver, people remember that. If you’re consistently dishonest, that’s a very hard reputation to shake off.’
Let’s be cautious in our claims then smash it!
Have more recent developments in longevity science been decreasingly spectacular? And is this because we’re all focussed on the same hallmarks of ageing?
Our best intervention in mice is calorie restriction—which isn’t a drug, and the strongest result was published in 1986!!
This is why he wants to try ONE MILLION MOLECULES in his wormbot: if we’re going to put some more exciting things on this graph, we need to try LOTS OF THINGS!
In the 90s and 00s we did knock out a lot of genes in worms…but there’s much more to try.
Matt: I was asked why I didn’t include more gene therapies on this slide, so here you go (red). Longevity intervention discovery has stagnated. We need a few pragmatic moonshots not more press releases hyping incremental results
In this episode, we’ll hear first from Matt Kaeberlein, the CEO of a company called Optispan…
Our second speaker is João Pedro de Magalhães who is the Chair of Molecular Biogerontology at the University of Birmingham, where he leads the genomics of aging and rejuvenation lab
Third is Steve Horvath, who has just retired from his position as a professor at the University of California, Los Angeles, and is now a Principal Investigator at Altos Labs in Cambridge.
The episode rounds off with an interview with Tom Lawry, Managing Director for Second Century Tech, who refers to himself as a recovering Microsoft executive. We discuss his recent bestselling book “Hacking Healthcare”